Life Sciences Partners Completes €280M Fundraise, Becomes Europe's Largest Life Science Investment Firm
Recently, European Life Sciences Investment GroupLSP(Life Sciences Partners)Announced the Completion of the Acquisition in IrelandVivasureMedical Group'sCround of investment. This is alsoLSPThe successful closing of the life sciences fund’s latest investment. The group has already exceeded its targets.280 millionInvestment, becoming Europe's largest life sciences fund organization.
Vivasure, the recipient of this investment, is a leading European medical device company. Its PerQseal platform has developed a percutaneous vascular bioresorbable closure system for large-bore arterial access, enabling minimally invasive procedures without leaving behind metallic implants or foreign sutures. This approach shortens patient recovery time and reduces healthcare costs. The technology has currently obtained CE marking in the European Union.
Anne Portwich, spokesperson for LSP, stated at a press conference, “We are pleased to invest in and support this innovative company. With commercialization in the EU and US markets, there is potential to improve patient outcomes. We look forward to working closely with Vivasure to continue gathering additional data through clinical studies, which will help drive adoption in the European market and facilitate regulatory approval in the US market, thereby enabling further commercialization.”
René Kuijten of LSP believes that this over-subscription in investment demonstrates LSP’s strong financial capacity and underscores its determination to meet the challenges of life sciences investing. This has not only raised LSP’s profile among numerous seasoned institutional investors but also attracted strategic partners such as Bristol-Myers Squibb, which views LSP as an investment partner for technological innovation in the European market.
LSP has invested in nine companies, including Neuravi, an Irish medical device company active in the acute ischemic stroke market; Nouscom, a Switzerland-based immuno-oncology company; and Kuros, which focuses on tissue repair and regeneration and was recently listed on the SIX Swiss Exchange.
Currently, the company is planning to seek investments in 20 companies, covering areas such as drug development, medical devices, and diagnostics. LSP has helped several well-known life sciences companies grow and expand, including the Dutch companies Crucell, Merus, Prosensa, and Sapiens; the Belgian companies Argenx and Movetis; the German companies Activaero, Jerini, and U3 Pharma; the Swiss company Okairos; and the New Zealand-based Danish pharmaceutical company.
Kuijten added, “European science has reached new heights, and the healthcare industry is gaining strong momentum. There are many investment opportunities in this field, and we will continue to explore these avenues, as always.”
LSP (Life Sciences Partners) is an independent European investment firm providing financing to private and public life sciences companies. LSP’s mission is to serve as a bridge between investors and technology holders, addressing the needs of the healthcare market. Since the 1980s, LSP has invested in approximately 100 innovative companies, many of which have become global leaders in the life sciences industry. With total investments exceeding $1.2 billion, LSP currently maintains offices in Amsterdam, Munich, and Boston. As a leading life sciences investor in Europe, LSP not only invests in the life sciences sector but also invests in public companies through the LSP Life Sciences Fund, which is listed on Euronext.
Launched in 2014, LSP5 primarily aims to invest in healthcare wage-related sectors and develop pioneering products and technologies to provide solutions that meet medical needs, similar to its predecessor fund. The fund will invest in approximately 20 companies involved in drug development, medical devices, and diagnostics.